NCT05688436View on ClinicalTrials.gov

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

RecruitingOBSERVATIONAL
Enrollment

1,178

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

January 17, 2031

Study Completion Date

January 17, 2031

Conditions
Multiple Sclerosis
Interventions
DRUG

Diroximel Fumarate

Administered as specified in the treatment arm.

BIOLOGICAL

Alemtuzumab

Administered as specified in the treatment arm.

DRUG

Fingolimod

Administered as specified in the treatment arm.

DRUG

Glatiramer acetate

Administered as specified in the treatment arm.

BIOLOGICAL

Interferon beta

Administered as specified in the treatment arm.

BIOLOGICAL

Natalizumab

Administered as specified in the treatment arm.

BIOLOGICAL

Ocrelizumab

Administered as specified in the treatment arm.

BIOLOGICAL

Ofatumumab

Administered as specified in the treatment arm.

DRUG

Ozanimod

Administered as specified in the treatment arm.

BIOLOGICAL

Peginterferon beta-1a

Administered as specified in the treatment arm.

DRUG

Ponesimod

Administered as specified in the treatment arm.

DRUG

Siponimod

Administered as specified in the treatment arm.

Trial Locations (1)

55344-2503

RECRUITING

OptumInsight, Eden Prairie

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY